nach oben

Erschienen in:

27.06.2022 | Original Article

Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis

verfasst von: Ryo Fujita, Tsutomu Endo, Masahiko Takahata, Kentaro Haraya, Hisataka Suzuki, Itaru Oda, Masahiro Kanayama, Tsuyoshi Asano, Keiichi Shigenobu, Akira Iwata, Katsuhisa Yamada, Hirohito Takeuchi, Hisanori Ohura, Daisuke Yoneoka, Norimasa Iwasaki

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Introduction

A 28.2 μg twice-weekly formulation of teriparatide (2/W-TPD) was developed to provide comparably high efficacy for osteoporosis to a 56.5 μg once-weekly formulation while improving the safety and persistence rate. In the current study, we aimed to elucidate the real-world persistence of 2/W-TPD and to identify the factors associated with the discontinuation of 2/W-TPD in patients with severe osteoporosis.

Materials and methods

This retrospective study included 90 patients who were treated with 2/W-TPD at three hospitals in Japan. Patient information was collected, including age, sex, distance to the hospital, family structure, comorbidities, previous treatment for osteoporosis, timing of the injection, side effects and duration of 2/W-TPD treatment, barthel index (BI), and bone mineral density (BMD) of the lumbar spine and femoral neck. We examined the factors influencing 2/W-TPD discontinuation using the Cox proportional hazards model.

Results

The 12 month completion rate of 2/W-TPD therapy was 47.5%. The Cox hazard analysis identified side effects [Hazard Ratio (HR) = 14.59, P < 0.001], low BMD of the femoral neck (HR = 0.04, P = 0.002), and morning injection (HR = 3.29, P = 0.006) as risk factors influencing the discontinuation of 2/W-TPD. Other variables, including age, did not contribute to the continuation of 2/W-TPD.

Conclusion

One year continuation rate of 2/W-TPD was higher than the previously reported value of the once-weekly formulation in real-world setting, probably due to the lower incidence of side effects. Introducing injection of 2/W-TPD may further improve the persistence of TPD therapy for osteoporosis.

Melton LJ, Chrischilles EA, Cooper C, Lane AW, Riggs BL (1992) Perspective how many women have osteoporosis? (In Eng). J Bone Miner Res 7:1005–1010. https://doi.org/10.1002/jbmr.5650070902CrossRefPubMed

Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733. https://doi.org/10.1007/s00198-006-0172-4CrossRefPubMed

Komatsubara S, Mori S, Mashiba T, Nonaka K, Seki A, Akiyama T, Miyamoto K, Cao Y, Manabe T, Norimatsu H (2005) Human parathyroid hormone (1–34) accelerates the fracture healing process of woven to lamellar bone replacement and new cortical shell formation in rat femora. Bone 36:678–687. https://doi.org/10.1016/j.bone.2005.02.002CrossRefPubMed

Andreassen TT, Ejersted C, Oxlund H (1999) Intermittent parathyroid hormone (1–34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 14:960–968. https://doi.org/10.1359/jbmr.1999.14.6.960CrossRefPubMed

Peichl P, Holzer LA, Maier R, Holzer G (2011) Parathyroid hormone 1–84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am 93:1583–1587. https://doi.org/10.2106/JBJS.J.01379CrossRefPubMed

Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB, Treatment of osteoporosis with parathyroid hormone study group (2007) Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146:326–339. https://doi.org/10.7326/0003-4819-146-5-200703060-00005CrossRefPubMed

Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M (2012) Randomized teriparatide [human parathyroid hormone (PTH) 1–34] once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097–3106. https://doi.org/10.1210/jc.2011-3479CrossRefPubMed

Ito M, Oishi R, Fukunaga M, Sone T, Sugimoto T, Shiraki M, Nishizawa Y, Nakamura T (2014) The effects of once-weekly teriparatide on hip structure and biomechanical properties assessed by CT. Osteoporos Int 25:1163–1172. https://doi.org/10.1007/s00198-013-2596-yCrossRefPubMed

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441. https://doi.org/10.1056/NEJM200105103441904CrossRefPubMed

10.

Yamane H, Takakura A, Shimadzu Y, Kodama T, Lee JW, Isogai Y, Ishizuya T, Takao-Kawabata R, Iimura T (2017) Acute development of cortical porosity and endosteal naïve bone formation from the daily but not weekly short-term administration of PTH in rabbit. PLoS ONE 12:e0175329. https://doi.org/10.1371/journal.pone.0175329CrossRefPubMedPubMedCentral

11.

Adachi JD, Hanley DA, Lorraine JK, Yu M (2007) Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study. Clin Ther 29:2055–2067. https://doi.org/10.1016/j.clinthera.2007.09.024CrossRefPubMed

12.

Usui T, Funagoshi M, Seto K, Ide K, Tanaka S, Kawakami K (2018) Persistence of and switches from teriparatide treatment among women and men with osteoporosis in the real world: a claims database analysis. Arch Osteoporos 13:54. https://doi.org/10.1007/s11657-018-0466-0CrossRefPubMed

13.

Sugimoto T, Shiraki M, Fukunaga M, Kishimoto H, Hagino H, Sone T, Nakano T, Ito M, Yoshikawa H, Minamida T, Tsuruya Y, Nakamura T (2019) Study of twice-weekly injections of teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study. Osteoporos Int 30:2321–2331. https://doi.org/10.1007/s00198-019-05111-6CrossRefPubMedPubMedCentral

14.

Fauci AS, Lane HC, Redfield RR (2020) Covid-19 navigating the uncharted. N Engl J Med 382:1268–1269. https://doi.org/10.1056/NEJMe2002387CrossRefPubMedPubMedCentral

15.

Marcus R, Wang O, Satterwhite J, Mitlak B (2003) The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 18:18–23. https://doi.org/10.1359/jbmr.2003.18.1.18CrossRefPubMed

16.

Shiraki M, Kuroda T, Miyakawa N, Fujinawa N, Tanzawa K et al (2011) Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: rationale, aims and organization of a Japanese osteoporosis intervention trial (JOINT) initiated by the research group of adequate treatment of osteoporosis (A-TOP). J Bone Miner Metab 29:37–43. https://doi.org/10.1007/s00774-010-0188-xCrossRefPubMed

17.

Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH (2005) Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 90:1583–1587. https://doi.org/10.1210/jc.2004-0826CrossRefPubMed

18.

Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148. https://doi.org/10.1002/jbmr.5650080915CrossRefPubMed

19.

Asahi Kasei Pharma Corporation (2021) Self-injection instruction manual for Teribone 28.2-µg subcutaneous autoinjector (in Japanese). https://static.akp-pharma-digital.com/article_objects/2021/06/30/08d784fee078.pdf. Accessed 12 Jan 2022

20.

Ranhoff AH, Laake K (1993) The Barthel ADL index: scoring by the physician from patient interview is not reliable. Age Ageing 22:171–174. https://doi.org/10.1093/ageing/22.3.171CrossRefPubMed

21.

Watanabe S, Iida Y, Ito T, Mizutani M, Morita Y, Suzuki S, Nishida O (2018) Effect of early rehabilitation activity time on critically Ill patients with intensive care unit-acquired weakness: a Japanese retrospective multicenter study. Prog Rehabil Med 3:20180003. https://doi.org/10.2490/prm.20180003CrossRefPubMedPubMedCentral

22.

Rajzbaum G, Grados F, Evans D, Liu-Leage S, Petto H, Augendre-Ferrante B (2014) Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: results from the European forsteo observational study. Joint Bone Spine 81:69–75. https://doi.org/10.1016/j.jbspin.2013.05.001CrossRefPubMed

23.

Kyvernitakis I, Kostev K, Kurth A, Albert US, Hadji P (2014) Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider. Osteoporos Int 25:2721–2728. https://doi.org/10.1007/s00198-014-2810-6CrossRefPubMed

24.

Foster SA, Foley KA, Meadows ES, Johnston JA, Wang SS, Pohl GM, Long SR (2011) Adherence and persistence with teriparatide among patients with commercial, medicare, and medicaid insurance. Osteoporos Int 22:551–557. https://doi.org/10.1007/s00198-010-1297-zCrossRefPubMed

25.

Ziller V, Zimmermann SP, Kalder M, Ziller M, Seker-Pektas B, Hellmeyer L, Hadji P (2010) Adherence and persistence in patients with severe osteoporosis treated with teriparatide. Curr Med Res Opin 26:675–681. https://doi.org/10.1185/03007990903538409CrossRefPubMed

26.

Arden NK, Earl S, Fisher DJ, Cooper C, Carruthers S, Goater M (2006) Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos Int 17:1626–1629. https://doi.org/10.1007/s00198-006-0171-5CrossRefPubMed

27.

Fujimori K, Sakurazawa K, Nakafuji S (2019) Analysis of the persistence and compliance of medications for osteoporosis using E-claim database (in Japanese). J Jpn Osteoporos Soc 5:69–77 ((in Japanese))

28.

Tsuchie H, Miyakoshi N, Kasukawa Y, Abe H, Masutani N, Shimada Y (2020) Factors affecting continuation of weekly teriparatide administration in rural areas. J Bone Miner Metab 38:248–253. https://doi.org/10.1007/s00774-019-01051-7CrossRefPubMed

29.

Mok LL, Nickols GA, Thompson JC, Cooper CW (1989) Parathyroid hormone as a smooth muscle relaxant. Endocr Rev 10:420–436. https://doi.org/10.1210/edrv-10-4-420CrossRefPubMed

30.

Omura F (2016) Decrease of blood pressure after once-weekly teriparatide administration and the prevention (in Japanese). J New Rem Clin 65:20–33

31.

Michalska D, Luchavova M, Zikan V, Raska I, Kubena AA, Stepan JJ (2012) Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis. Osteoporos Int 23:2885–2891. https://doi.org/10.1007/s00198-012-1955-4CrossRefPubMed

32.

Vik SA, Jantzi M, Poss J, Hirdes J, Hanley DA, Hogan DB, Maxwell CJ (2007) Factors associated with pharmacologic treatment of osteoporosis in an older home care population. J Gerontol A Biol Sci Med Sci 62:872–878. https://doi.org/10.1093/gerona/62.8.872CrossRefPubMed

33.

Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R (2007) Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110:1860–1867. https://doi.org/10.1002/cncr.22991CrossRefPubMed

34.

Moriwaki K, Noto S (2017) Economic evaluation of osteoporosis liaison service for secondary fracture prevention in postmenopausal osteoporosis patients with previous hip fracture in Japan. Osteoporos Int 28:621–632. https://doi.org/10.1007/s00198-016-3777-2CrossRefPubMed

Titel: Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis
verfasst von: Ryo Fujita
Tsutomu Endo
Masahiko Takahata
Kentaro Haraya
Hisataka Suzuki
Itaru Oda
Masahiro Kanayama
Tsuyoshi Asano
Keiichi Shigenobu
Akira Iwata
Katsuhisa Yamada
Hirohito Takeuchi
Hisanori Ohura
Daisuke Yoneoka
Norimasa Iwasaki
Publikationsdatum: 27.06.2022
Verlag: Springer Nature Singapore
Erschienen in: Journal of Bone and Mineral Metabolism / Ausgabe 5/2022
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-022-01347-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis